Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04043195
Recruitment Status : Not yet recruiting
First Posted : August 2, 2019
Last Update Posted : August 2, 2019
Sponsor:
Information provided by (Responsible Party):
Hatim Husain, University of California, San Diego

Brief Summary:

The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with certain immunotherapies (drugs that target the immune system).

Nivolumab (Opdivo®) is approved by the Food and Drug Administration (FDA) for the treatment of metastatic (the cancer has spread) NSCLC. It is a type of drug called a monoclonal antibody (a type of protein). Monoclonal antibodies bind to other proteins, such as PD-1 (programmed cell death-1), on immune cells, which allows the immune cells to continue working against the tumor.

Ipilumumab (Yervoy®) is also a monoclonal antibody, but binds to a protein called CTLA-4 (cytotoxic T-lymphocyte-associated protein 4).

Oxaliplatin is a type of immunogenic chemotherapy, which may increase the body's immune response to the cancer. Both are approved for treatment of other types of cancers, but not in patients with NSCLC.


Condition or disease Intervention/treatment Phase
Advanced NSCLC Drug: Nivolumab Drug: Oxaliplatin Drug: Ipilimumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Nivolumab (Anti-PD1 Antibody) and Ipilimumab (Anti-CTLA4 Antibody) in Combination With Immunogenic Chemotherapy for Patients With Advanced Non-Small Cell Lung Cancer
Estimated Study Start Date : August 2019
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Nivolumab + Oxaliplatin
Cohort 1
Drug: Nivolumab
240 mg every 2 weeks. Nivolumab will continue for up to 2 years.

Drug: Oxaliplatin
65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.

Experimental: Nivolumab + Oxaliplatin + Ipilimumab
Cohort 2
Drug: Nivolumab
240 mg every 2 weeks. Nivolumab will continue for up to 2 years.

Drug: Oxaliplatin
65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.

Drug: Ipilimumab
1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: 4 months ]
    To estimate ORR by RECIST 1.1


Secondary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 1 and 2 year ]
  2. Progression-free survival (PFS) [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

The following list is a summary. Additional criteria apply.

Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for study entry.

  • At least 18 years or older
  • Histologically or cytologically confirmed, advanced non-squamous or squamous NSCLC
  • Last line of therapy for advanced non-squamous or squamous NSCLC must be with an anti-PD1 or PDL1 antibody with confirmed progression on or after that treatment. Patients may have received no more than 3 lines of prior therapy including no more than 2 prior lines of therapy containing a PD-(L)-2 antibody. Patients must have received prior cisplatin or carboplatin based doublet chemotherapy.
  • Measurable disease, as defined by RECIST v1.1
  • Adequate hematologic and end-organ function, defined by the laboratory test results within 14 days prior to randomization:
  • For female patients of childbearing potential and male patients with partners of childbearing potential, agreement to use a highly effective form(s) of contraception during study treatment that results in a low failure rate of <1% per year when used consistently and correctly. Female patients should continue contraception use for 5 months after the last dose of nivolumab and ipilimumab and for 6 months after the last dose of oxaliplatin. Make patients treated with chemotherapy should continue contraception use for 7 months after the last dose of chemotherapy. Men should refrain from donating sperm during this same period. Such methods include combined (estrogen and progestogen containing) hormonal contraception, with another additional barrier method always containing a spermicide, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion or vasectomized partner (on the understanding that this is the only one partner during the study duration), and sexual abstinence.

    • Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drug. The same rules are valid for male patients involved in this study if they have a partner of childbearing potential. Male patients must always use a condom.
    • Women who are not postmenopausal (>12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug.

Exclusion Criteria:

General Medical Exclusions

  • Women who are pregnant, lactating, or intending to become pregnant during the study.
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
  • History of autoimmune disease
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
  • Major surgical procedure other than for diagnosis within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study.
  • Prior allogeneic bone marrow transplantation or solid organ transplantation.

Exclusion Criteria Related to Medications

  • Treatment with any approved anti-cancer therapy within 2 weeks prior to initiation of study treatment.
  • Treatment with any other investigational agent with therapeutic intent within 21 days prior to enrollment.
  • Received therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to enrollment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04043195


Contacts
Layout table for location contacts
Contact: Hatim Husain (858) 534-1590 hhusain@ucsd.edu
Contact: Sarah Moore (858) 822-5677 sam055@ucsd.edu

Locations
Layout table for location information
United States, California
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Sponsors and Collaborators
Hatim Husain
Investigators
Layout table for investigator information
Principal Investigator: Hatim Husain University of California, San Diego

Layout table for additonal information
Responsible Party: Hatim Husain, Associate Professor, University of California, San Diego
ClinicalTrials.gov Identifier: NCT04043195     History of Changes
Other Study ID Numbers: 181485
First Posted: August 2, 2019    Key Record Dates
Last Update Posted: August 2, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hatim Husain, University of California, San Diego:
NSCLC
Ipilimumab
Nivolumab
Oxaliplatin
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Nivolumab
Ipilimumab
Oxaliplatin
Antineoplastic Agents, Immunological
Antineoplastic Agents